Last reviewed · How we verify
TERIPARATIDE
At a glance
| Generic name | TERIPARATIDE |
|---|---|
| Drug class | Parathyroid Hormone Analog [EPC] |
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
Common side effects
- Pain
- Nausea
- Arthralgia
- Headache
- Asthenia
- Hypertension
- Dizziness
- Rhinitis
- Cough increased
- Gastritis
- Pneumonia
- Dyspnea
Key clinical trials
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
- Effect of Mechanical Loading With PTH on Cortical Bone (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TERIPARATIDE CI brief — competitive landscape report
- TERIPARATIDE updates RSS · CI watch RSS